Innate immune targets of hepatitis B virus infection

• Published in: World journal of hepatology Vol. 8; no. 17; pp. 716 - 725
• Main Authors: Zou, Zhi-Qiang, Wang, Li, Wang, Kai, Yu, Ji-Guang
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 18.06.2016
• Subjects: Hepatitis; immune; pathway; response;Signaling; Topic Highlight; virus;Infection;Targets;Innate; Infection; Targets; Hepatitis B virus; Signaling pathway; Innate immune response
• ISSN: 1948-5182; 1948-5182
• DOI: 10.4254/wjh.v8.i17.716

Approximately 400 million people are chronically infected with hepatitis B virus(HBV) globally despitethe widespread immunization of HBV vaccine and the development of antiviral therapies. The immunopathogenesis of HBV infection is initiated and driven by complexed interactions between the host immune system and the virus. Host immune responses to viral particles and proteins are regarded as the main determinants of viral clearance or persistent infection and hepatocyte injury. Innate immune system is the first defending line of host preventing from virus invasion. It is acknowledged that HBV has developed active tactics to escape innate immune recognition or actively interfere with innate immune signaling pathways and induce immunosuppression, which favor their replication. HBV reduces the expression of pattern-recognition receptors in the innate immune cells in humans. Also, HBV may interrupt different parts of antiviral signaling pathways, leading to the reduced production of antiviral cytokines such as interferons that contribute to HBV immunopathogenesis. A full comprehension of the mechanisms as to how HBV inactivates various elements of the innate immune response to initiate and maintain a persistent infection can be helpful in designing new immunotherapeutic methods for preventing and eradicating the virus. In this review, we aimed to summarize different branches the innate immune targeted by HBV infection. The review paper provides evidence that multiple components of immune responses should be activated in combination with antiviral therapy to disrupt the tolerance to HBV for eliminating HBV infection.